Pleural Effusion - Emergency Management

Quick Answer

One-liner: Pleural effusion is abnormal fluid accumulation in the pleural space requiring emergency management when causing respiratory compromise, haemodynamic instability (tension hydrothorax), or infection (empyema).

Pleural effusion affects 1.5 million people annually in developed countries, with causes ranging from transudative (CHF, cirrhosis) to exudative (infection, malignancy, PE). Emergency presentations include massive effusions causing respiratory failure, tension hydrothorax with mediastinal shift, empyema requiring urgent drainage, and haemothorax from trauma. Light's criteria differentiate transudate from exudate. Ultrasound-guided thoracentesis is the gold standard for diagnosis and initial treatment. Limit drainage to 1.0-1.5L per session to prevent re-expansion pulmonary oedema (REPE). Empyema requires chest drain insertion, antibiotics, and may need intrapleural fibrinolytics (tPA/DNase) or VATS.

---

ACEM Exam Focus

Primary Exam Relevance

• Anatomy: Pleural space anatomy, visceral and parietal pleura, intercostal neurovascular bundle (lies inferior to each rib), diaphragm attachments, costodiaphragmatic recesses
• Physiology: Starling forces in pleural fluid dynamics (hydrostatic vs oncotic pressure), lymphatic drainage of pleural space, pleural fluid turnover (0.2-0.5ml/kg/day), negative intrapleural pressure (-5 cmH2O at FRC)
• Pharmacology: Intrapleural fibrinolytics (tPA, DNase), local anaesthetics, empiric antibiotics for empyema, diuretics for transudative effusions

Fellowship Exam Relevance

• Written: Light's criteria application and limitations, pleural fluid analysis interpretation, indications for chest drain insertion, MIST2 trial (tPA/DNase), re-expansion pulmonary oedema prevention, malignant vs parapneumonic effusion management
• OSCE: Ultrasound-guided thoracentesis procedure, chest drain insertion, pleural fluid interpretation, communication with patient about drainage procedures
• Key domains tested: Medical Expert (diagnosis and management), Collaborator (working with respiratory medicine, cardiothoracics), Communicator (consent, explaining procedures)

---

Key Points

---

Epidemiology

Australian/NZ Specific

• Aboriginal and Torres Strait Islander children have 3-5x higher rates of empyema compared to non-Indigenous children [12]
• Streptococcus pneumoniae remains the leading cause, but Staphylococcus aureus (including MRSA) is increasingly common in Indigenous communities [13]
• Remote/rural presentations often delayed 24-72 hours due to access barriers, resulting in more advanced disease at presentation [14]
• RFDS retrieves approximately 150-200 patients annually with pleural infection requiring tertiary care [15]

---

Pathophysiology

Mechanism of Pleural Fluid Accumulation

Normal pleural fluid dynamics:

• Pleural fluid turnover: 0.2-0.5 ml/kg/day (~10-20 ml total volume)
• Entry: Systemic capillaries in parietal pleura (hydrostatic pressure gradient)
• Exit: Lymphatic stomata in parietal pleura (can absorb up to 500 ml/day)
• Balance maintained by Starling forces

Transudative effusion (systemic factors):

• Increased hydrostatic pressure (CHF, constrictive pericarditis)
• Decreased oncotic pressure (cirrhosis, nephrotic syndrome, hypoalbuminaemia)
• Increased negative pleural pressure (atelectasis)

Exudative effusion (local pleural factors):

• Increased capillary permeability (infection, malignancy, inflammation)
• Impaired lymphatic drainage (malignant infiltration, radiation)
• Transdiaphragmatic fluid movement (ascites with hepatic hydrothorax)

Pathological Progression of Parapneumonic Effusion

Pneumonia → Exudative Phase (48-72h) → Fibrinopurulent Phase (3-14 days) → Organizing Phase (greater than 14 days)
    ↓              ↓                            ↓                              ↓
Simple effusion   Sterile exudate         Bacterial invasion         Fibrosis, trapped lung
(pH greater than 7.3)        (pH 7.2-7.3)              Loculations, pus            (requires VATS)
                                            (pH below 7.2)

Stage 1 - Exudative (Simple parapneumonic):

• Sterile fluid from increased capillary permeability
• pH greater than 7.3, glucose greater than 3.4 mmol/L, LDH below 1000 IU/L
• Usually resolves with antibiotics alone

Stage 2 - Fibrinopurulent (Complicated parapneumonic/Early empyema):

• Bacterial invasion of pleural space
• Fibrin deposition → loculations and septations
• pH below 7.2, glucose below 3.4 mmol/L, LDH greater than 1000 IU/L
• Requires drainage + antibiotics

Stage 3 - Organizing (Established empyema):

• Fibroblast proliferation, thick pleural peel
• "Trapped lung"
• cannot re-expand
• Requires surgical decortication (VATS/thoracotomy)

Tension Hydrothorax

Massive pleural effusion can cause haemodynamic compromise through:

• Mediastinal shift → IVC/SVC compression → reduced venous return
• Direct cardiac compression → reduced diastolic filling
• Contralateral lung compression → hypoxia
• Mechanism similar to tension pneumothorax (obstructive shock)

Key difference from tension pneumothorax: Develops more gradually (hours-days vs minutes), dullness to percussion (not hyperresonance)

Why It Matters Clinically

Understanding pathophysiology guides management:

1. Transudates (CHF, cirrhosis) → treat underlying cause, diuretics, usually don't require drainage unless symptomatic
2. Exudates (infection, malignancy) → require drainage and cause-specific treatment
3. Stage of parapneumonic effusion determines if antibiotics alone vs drainage vs surgery
4. pH below 7.2 is the most reliable predictor of need for drainage [16]

---

Clinical Approach

Recognition

Think Pleural Effusion Emergency When:

• Respiratory distress with dullness to percussion on one side
• Fever + pleuritic chest pain + recent pneumonia (empyema)
• Known malignancy with progressive dyspnoea
• Decompensated heart failure not responding to diuretics
• Trauma with haemodynamic instability (haemothorax)
• Post-procedure (central line, thoracentesis) with deterioration

Initial Assessment

Primary Survey

A - Airway:

• Usually patent unless massive effusion with severe respiratory distress
• May require non-invasive ventilation (NIV) as bridge to drainage
• Intubation rarely needed if drainage performed promptly

B - Breathing:

C - Circulation:

D - Disability:

• Confusion may indicate hypoxia or sepsis
• GCS usually preserved unless severe respiratory failure

E - Exposure:

• Fever (empyema, parapneumonic)
• Cachexia (malignancy)
• Signs of cirrhosis (ascites, jaundice, spider naevi)
• Signs of heart failure (peripheral oedema, elevated JVP)
• Chest wall trauma, surgical scars

History

Key Questions

Red Flag Symptoms

Examination

General Inspection

• Position: Sitting upright, leaning forward (orthopnoea)
• Respiratory effort: Use of accessory muscles, nasal flaring
• Colour: Pallor (anaemia, haemothorax), cyanosis (severe hypoxia)
• Cachexia (malignancy, chronic illness)
• Stigmata of underlying disease (CHF, cirrhosis, malignancy)

Specific Findings

---

Investigations

Immediate (Resus Bay)

Point-of-Care Ultrasound (Gold Standard for Detection)

POCUS is more sensitive than CXR for detecting pleural effusion [17]

• CXR requires greater than 200-300ml to detect (PA view) or greater than 50ml (lateral decubitus)
• Ultrasound detects as little as 20ml

Technique

• Low-frequency curvilinear or phased array probe (2-5 MHz)
• Patient sitting upright (if possible) or supine
• Scan posterolateral chest at base, just above diaphragm
• Identify: Liver/spleen → diaphragm → pleural space → lung

Findings in Pleural Effusion

Pre-Thoracentesis Ultrasound (MANDATORY)

BTS 2023 Guidelines: Ultrasound guidance is standard of care for thoracentesis [18]

Pre-procedure ultrasound should document:

1. Depth of effusion (greater than 15mm for safe drainage)
2. Diaphragm position (avoid puncture - moves with respiration)
3. Presence of septations (may limit drainage, predict need for intervention)
4. Optimal puncture site (mark with permanent marker)
5. Lung position (ensure lung is not immediately beneath puncture site)

Standard ED Workup

Pleural Fluid Analysis (Light's Criteria)

Light's Criteria for Exudate (meets ≥1 of following): [19]

• Sensitivity: 98% (rarely misses exudate)
• Specificity: 83% (may misclassify transudate as exudate in diuretic-treated CHF patients)

Serum-Effusion Albumin Gradient: If clinical suspicion for transudate is high but Light's criteria suggests exudate:

• Serum albumin - Pleural albumin greater than 1.2 g/dL = transudate
• Useful in diuretic-treated CHF patients [20]

Complete Pleural Fluid Analysis

pH below 7.2 is the most reliable single indicator for need to drain [21]

Additional Pleural Fluid Tests

Advanced/Specialist

Chest X-ray Findings

PA Erect CXR:

• Blunted costophrenic angle (requires greater than 200ml)
• Meniscus sign (fluid rising up lateral chest wall)
• Homogeneous opacity with concave upper border
• Mediastinal shift away (if large greater than 1L)

Lateral Decubitus CXR:

• Layering of free-flowing fluid
• Loculation suspected if fluid doesn't layer
• More sensitive than PA view (detects greater than 50ml)

Supine CXR (common in resus):

• Increased haziness over hemithorax (not well-demarcated)
• Apical cap sign (fluid tracks to apex when supine)
• Less sensitive - often missed

---

Management

Immediate Management (First 15 Minutes)

1. Call for help - Senior ED doctor, respiratory medicine (0-30 sec)
2. High-flow oxygen 15L non-rebreather (target SpO2 greater than 94%) (30-60 sec)
3. IV access x2, bloods including VBG, coagulation (1-2 min)
4. Cardiac monitoring, SpO2 continuous (1-2 min)
5. POCUS to confirm effusion, estimate size, mark drainage site (3-5 min)
6. Decision: Urgent thoracentesis vs chest drain vs supportive care (5-10 min)
7. Prepare for procedure: Consent, position, equipment (10-15 min)

Decision Framework: Who Needs Drainage?

Ultrasound-Guided Thoracentesis

Indications:

• Diagnostic: Any new effusion of unknown aetiology
• Therapeutic: Symptomatic relief of large effusion (dyspnoea)
• Emergency: Tension hydrothorax, massive effusion with respiratory failure

Contraindications (relative):

• Coagulopathy (INR greater than 1.5, platelets below 50) - correct first if possible
• Small effusion (below 10mm depth on ultrasound)
• Uncooperative patient
• Overlying cellulitis

Procedure: [22]

1. Position patient:
   - Sitting upright, leaning forward over bedside table (optimal)
   - Lateral decubitus with affected side up (alternative)
   - Supine with head elevated 30-45° (if unable to sit)

2. Ultrasound localisation:
   - Mark site of maximal fluid depth (greater than 15mm)
   - Mark diaphragm position
   - Note lung position
   - Mark puncture site with permanent marker

3. Prepare equipment:
   - Sterile drape, gloves, gown
   - Chlorhexidine skin prep
   - Lignocaine 1% (10-20ml)
   - 22G needle for local anaesthetic
   - 16-18G thoracentesis needle or catheter
   - 50ml syringe, three-way tap
   - Drainage bag or vacuum bottles

4. Anaesthetise:
   - Local anaesthetic to skin, subcutaneous tissue, intercostal muscles
   - Infiltrate down to parietal pleura
   - Advance needle OVER the TOP of the rib (neurovascular bundle runs inferior)

5. Insert thoracentesis needle:
   - Perpendicular to chest wall, just above rib
   - Advance while aspirating
   - "Pop" and fluid return confirms pleural space entry

6. Drain fluid:
   - Diagnostic: 50-100ml into specimen tubes
   - Therapeutic: Maximum 1.0-1.5L (prevent REPE)
   - Stop if: chest tightness, cough, SpO2 drops, resistance to drainage

7. Send samples:
   - Biochemistry: Protein, LDH, glucose, pH
   - Microbiology: Gram stain, culture (aerobic, anaerobic), AFB
   - Cytology: If malignancy suspected

8. Post-procedure:
   - No routine CXR needed if ultrasound-guided and patient asymptomatic [23]
   - CXR if symptoms develop, multiple needle passes, or suspicion of pneumothorax
   - Monitor SpO2 for 1-2 hours

Chest Drain Insertion (Tube Thoracostomy)

Indications for Chest Drain (NOT just thoracentesis):

• Empyema: pH below 7.2, frank pus, positive Gram stain/culture
• Complicated parapneumonic effusion: pH 7.0-7.2, glucose below 3.4, LDH greater than 1000
• Haemothorax: Traumatic or iatrogenic
• Recurrent malignant effusion: (for pleurodesis or indwelling catheter)
• Large symptomatic effusion requiring repeated drainage

Drain Size Selection:

Site: Triangle of safety (same as pneumothorax)

• 5th intercostal space, mid-axillary line
• Superior to 5th rib (avoid neurovascular bundle)

Technique: Seldinger (preferred for small bore) or open (for large bore)

Post-insertion Management:

• Connect to underwater seal drainage (UWSD)
• Low-pressure suction if needed (-10 to -20 cmH2O)
• CXR to confirm position and lung re-expansion
• Monitor drainage output (record hourly initially)
• Flushing: 20ml saline every 6 hours prevents blockage (BTS 2023) [18]
• Daily CXR while drain in situ

Empyema Management

Initial Management (ED):

1. Chest drain insertion (10-14F small bore adequate in most cases)
2. IV antibiotics: Empiric broad-spectrum (cover streptococci, staphylococci, anaerobes)
   • Australian Therapeutic Guidelines: Ceftriaxone 2g IV daily + Metronidazole 500mg IV 8-hourly
   • OR Piperacillin-tazobactam 4.5g IV 8-hourly (if severe/ICU)
   • Add vancomycin if MRSA suspected (Indigenous communities, recent hospitalisation)
3. Resuscitation: Fluid if hypotensive, oxygen if hypoxic
4. Analgesia: Adequate pain control (fentanyl/morphine)

Intrapleural Fibrinolytic Therapy (MIST2 Trial): [5]

• Indicated for: Loculated effusion, inadequate drainage despite chest drain
• Regimen: tPA 10mg + DNase 5mg instilled twice daily for 3 days
• Outcomes: Reduced surgical referral (4% vs 16%), reduced hospital stay
• Note: tPA alone or DNase alone is NOT effective - must use combination

Surgical Referral:

• Persistent sepsis despite drainage and antibiotics
• Loculated effusion not responding to fibrinolytics
• Trapped lung (thick pleural peel preventing re-expansion)
• Options: VATS (preferred), thoracotomy with decortication

Malignant Pleural Effusion

ED Management:

• Therapeutic thoracentesis for symptom relief (dyspnoea)
• Limit to 1-1.5L to prevent REPE
• Refer to respiratory medicine/oncology for definitive management

Definitive Options (not ED decisions):

• Indwelling pleural catheter (IPC): Home drainage, repeated aspiration
• Talc pleurodesis: Chemical adhesion of pleura to prevent recurrence
• Repeat thoracentesis: For patients with poor prognosis

Medications

Paediatric Dosing

Ongoing Management

Monitoring:

• Vital signs: Temperature (resolving fever indicates treatment response)
• Drain output: Record volume and character (purulent → serous = improvement)
• CXR: Daily to monitor re-expansion, detect pneumothorax
• Inflammatory markers: CRP trending down indicates response

Drain Removal Criteria:

• Lung fully re-expanded on CXR
• Drain output below 200ml/24 hours
• Fluid non-purulent (serous)
• Patient afebrile for 24-48 hours
• No air leak (if pneumothorax component)

Definitive Care

Respiratory Medicine Referral:

• All exudative effusions (need definitive diagnosis)
• Recurrent effusions (need investigation)
• Malignant effusions (IPC, pleurodesis decisions)
• Complex parapneumonic effusions

Cardiothoracic Surgery Referral:

• Failed medical management (persistent sepsis, loculations)
• Trapped lung requiring decortication
• Haemothorax with ongoing bleeding (greater than 200ml/hr for 3 hours or greater than 1500ml initially)
• Bronchopleural fistula

---

Disposition

Admission Criteria

All patients with the following require admission:

• Empyema or complicated parapneumonic effusion
• Chest drain in situ
• Haemothorax
• Respiratory failure (requiring oxygen)
• Tension hydrothorax (even after stabilisation)
• Malignant effusion requiring further investigation/management
• Sepsis or haemodynamic instability

ICU/HDU Criteria

• Respiratory failure requiring NIV or intubation
• Septic shock requiring vasopressors
• Tension hydrothorax with haemodynamic instability
• Massive haemothorax with ongoing bleeding
• Multi-organ dysfunction

Discharge Criteria

Consider discharge if ALL of the following:

• Simple transudative effusion (e.g., CHF) with known cause
• Small effusion with minimal symptoms
• No hypoxia (SpO2 greater than 94% on room air)
• No signs of infection (afebrile, normal WCC, low CRP)
• Reliable patient with clear safety-netting

Discharge NOT appropriate for:

• Any chest drain in situ
• Empyema or complicated parapneumonic effusion
• Undiagnosed exudative effusion
• Symptomatic effusion not adequately drained

Follow-up

• GP follow-up: 3-5 days post-discharge (check for recurrence)
• Respiratory outpatient: 2-4 weeks (all exudative effusions)
• Repeat CXR: 4-6 weeks to confirm resolution
• CT chest: If malignancy suspected, recurrent effusion, or incomplete resolution
• Smoking cessation: Offer support (reduces infection recurrence)

---

Special Populations

Paediatric Considerations

Epidemiology:

• Empyema most common age 1-4 years
• Streptococcus pneumoniae most common cause (but serotype replacement post-vaccine) [26]
• Staphylococcus aureus causes more necrotising pneumonia with empyema
• Indigenous children: 3-5x higher incidence [12]

Management Differences:

• Lower threshold for drainage (children tolerate effusions poorly)
• Ultrasound-guided pigtail catheters (10-14F) equally effective as large bore
• Early use of intrapleural fibrinolytics reduces need for VATS [27]
• Children recover faster than adults (often discharged with oral antibiotics)

Pregnancy

Unique Considerations:

• Physiological pleural fluid may increase slightly in pregnancy
• Massive effusion rare, usually indicates significant pathology
• Most common causes: CHF (peripartum cardiomyopathy), PE, infection

Management Modifications:

• Thoracentesis is safe in pregnancy
• Left lateral tilt during procedure (avoid IVC compression)
• Limit drainage to prevent hypotension (fetal compromise)
• Antibiotic choice: Avoid fluoroquinolones; ceftriaxone/metronidazole safe
• CT chest: Shield abdomen, avoid unless essential

Elderly

Specific Considerations:

• Higher incidence of malignant effusions
• Increased mortality from empyema (25-30% vs 15% in younger adults)
• More comorbidities (CHF, cirrhosis) causing transudates
• May not mount fever response (empyema may be "cold")
• Higher risk of REPE (limit drainage carefully)
• DVT prophylaxis essential during admission

Indigenous Health

Important Note: Aboriginal, Torres Strait Islander, and Maori Considerations:

Epidemiology:

• Aboriginal and Torres Strait Islander children have 3-5x higher rates of empyema compared to non-Indigenous children [12]
• Higher rates of underlying risk factors: overcrowded housing, nutritional deficiencies, chronic suppurative lung disease, bronchiectasis
• Staphylococcus aureus (including MRSA) more prevalent in Indigenous communities [13]
• Maori have 2-3x higher respiratory infection hospitalisation rates [28]

Microbiology Differences:

• Higher rates of community-associated MRSA (CA-MRSA) - consider empiric vancomycin
• Streptococcus pyogenes (Group A Strep) causes severe pleuropulmonary infections
• Polymicrobial infections more common (underlying bronchiectasis)

Barriers to Care:

• Geographic remoteness: Delayed presentation (24-72 hours common in remote areas)
• Limited primary care access: Pneumonia progresses to empyema before treatment
• Distrust of healthcare system: May minimise symptoms, leave before treatment complete
• Language barriers: Use qualified interpreters for consent and education

Cultural Safety:

• Involve Aboriginal Liaison Officers / Maori Health Workers early
• Explain procedures clearly using visual aids
• Allow whanau (family) presence during procedures and discussions
• Respect cultural beliefs around invasive procedures
• Acknowledge historical trauma and work to build trust
• Consider discharge planning early (may need extended admission if remote)

Remote/Rural Specific:

• Limited ultrasound and procedural expertise in remote clinics
• May need to perform landmark-guided thoracentesis if no ultrasound
• Early RFDS/retrieval consultation for empyema
• Oral antibiotic completion may be challenging (medication supply, compliance)
• Close follow-up essential but often difficult to achieve

---

Remote/Rural Considerations

Pre-Hospital

Ambulance/First Responders:

• Recognise respiratory distress pattern (dullness, decreased breath sounds)
• High-flow oxygen, monitor SpO2
• Alert receiving hospital (may need to activate RFDS retrieval)
• Position: Upright if tolerated (improves ventilation)

Resource-Limited Setting

Minimum Equipment for Thoracentesis:

• 16-18G IV cannula (if no thoracentesis kit)
• 50ml syringe, three-way tap
• Sterile drape, antiseptic
• Lignocaine 1%
• Specimen containers

Modified Approach:

• If no ultrasound: Use clinical landmarks (posterior axillary line, 2 intercostal spaces below upper fluid level on percussion)
• Pneumothorax risk increases without ultrasound (3-10% vs below 1%)
• Lower threshold for chest drain if cannot perform serial thoracentesis
• Consider empiric antibiotics if empyema suspected (even before drainage)

Improvised Underwater Seal Drain:

1. Insert chest drain (or large IV cannula as temporising measure)
2. Attach to IV tubing
3. Place end in sterile water bottle (500ml) 
4. Submerge tubing 2-3cm below water surface
5. Observe for bubbling (air) or fluid drainage
6. Keep bottle below patient level

Retrieval

RFDS Retrieval Criteria:

• Empyema with sepsis
• Respiratory failure requiring ICU care
• Haemothorax
• Failed local management
• Need for cardiothoracic input

Pre-Retrieval Checklist:

• Chest drain in situ and functioning (if empyema/haemothorax)
• Antibiotics commenced
• Adequate analgesia for flight
• IV access secured
• Documentation complete (fluid analysis, imaging)
• Handover to retrieval team

During Air Retrieval:

• Monitor SpO2 (altitude effects on oxygenation)
• Ensure chest drain is patent (may need clamping during altitude changes)
• Have thoracentesis equipment available for emergencies
• Pressurised aircraft preferred

Telemedicine

When to Consult:

• Uncertain diagnosis (differentiate causes)
• Guidance on thoracentesis technique
• Pleural fluid interpretation
• Disposition decisions (who needs retrieval urgently)
• Troubleshooting (drain not draining)

What to Have Ready:

• Vital signs, clinical findings
• CXR/ultrasound images (can transmit via smartphone)
• Pleural fluid results
• Questions prepared

---

Pitfalls & Pearls

---

Viva Practice

---

OSCE Scenarios

Station 1: Ultrasound-Guided Thoracentesis

Format: Procedural station Time: 11 minutes Setting: ED procedure room with manikin/phantom

Candidate Instructions:

A 65-year-old man has a large right-sided pleural effusion causing dyspnoea. You are asked to perform ultrasound-guided diagnostic and therapeutic thoracentesis. Demonstrate your technique on the model provided. An assistant is available.

Examiner Instructions: Candidate should demonstrate systematic approach to ultrasound-guided thoracentesis including preparation, ultrasound localisation, procedure technique, and sample handling.

Marking Criteria:

Expected Standard:

• Pass: ≥8/14
• Key discriminators: Correct ultrasound localisation, sterile technique, needle insertion over rib, limiting volume to prevent REPE

---

Station 2: Pleural Fluid Interpretation

Format: Data interpretation station Time: 11 minutes Setting: ED workstation with lab results

Candidate Instructions:

You are presented with pleural fluid results from two patients. Interpret the results, determine the likely aetiology, and outline your management plan for each.

Data provided:

Patient A: 55-year-old with progressive dyspnoea, bilateral ankle swelling, on furosemide for heart failure

• Pleural fluid: Protein 22 g/L, LDH 120 IU/L, pH 7.45, Glucose 5.2 mmol/L, WCC 200/μL (lymphocytes)
• Serum: Protein 65 g/L, LDH 200 IU/L, Albumin 32 g/L

Patient B: 48-year-old with fever 38.5°C, productive cough, right-sided pleuritic pain for 4 days

• Pleural fluid: Protein 55 g/L, LDH 2500 IU/L, pH 6.9, Glucose 1.8 mmol/L, WCC 45,000/μL (95% neutrophils)
• Serum: Protein 70 g/L, LDH 250 IU/L

Marking Criteria:

Expected Standard:

• Pass: ≥8/14
• Key discriminators: Correct application of Light's criteria, recognising pH below 7.2 mandates drainage, appropriate management plans

---

Station 3: Breaking Bad News - Malignant Effusion

Format: Communication station Time: 11 minutes Setting: ED relatives room

Candidate Instructions:

You are the ED registrar. Mrs Smith, a 72-year-old, had a pleural effusion drained yesterday. Cytology has returned showing malignant cells consistent with lung adenocarcinoma. She has no known cancer history. She has been told to expect her results today. Please speak with her.

Actor/Patient Brief:

• You are worried but hoping for good news
• When told about cancer, become tearful and ask "How long do I have?"
• Ask if it can be cured
• Ask about telling your husband (who has dementia)

Marking Criteria:

Expected Standard:

• Pass: ≥7/13
• Key discriminators: Warning shot before diagnosis, responding to emotion, honest but compassionate prognosis discussion, offering practical support

---

SAQ Practice

Question 1 (8 marks)

Stem: A 58-year-old man presents with dyspnoea and right-sided pleuritic chest pain. He has a history of alcoholic liver cirrhosis. CXR shows a moderate right-sided pleural effusion.

Question: a) List 4 features of pleural fluid analysis that would differentiate a transudative from an exudative effusion using Light's criteria. (4 marks) b) What additional test would you perform if the fluid appears to be an exudate but you clinically suspect a transudate (e.g., hepatic hydrothorax)? Explain why. (2 marks) c) List 2 other causes of transudative pleural effusion besides cirrhosis. (2 marks)

Model Answer:

a) Light's Criteria features (1 mark each, max 4):

• Pleural protein / Serum protein ratio greater than 0.5 (exudate)
• Pleural LDH / Serum LDH ratio greater than 0.6 (exudate)
• Pleural LDH greater than 2/3 upper limit of normal for serum LDH (exudate)
• Fluid is exudate if ANY ONE criterion is met
• Sensitivity 98%, specificity 83% for exudates

b) Additional test (2 marks):

• Serum-effusion albumin gradient (1 mark)
• If serum albumin minus pleural albumin greater than 1.2 g/dL = transudate (1 mark)
• Rationale: Light's criteria misclassifies up to 25% of transudates as exudates, particularly in patients on diuretics (concentrates pleural proteins). The albumin gradient is unaffected by diuretics and helps correctly reclassify these cases.

c) Other causes of transudate (1 mark each, max 2):

• Congestive heart failure (most common)
• Nephrotic syndrome
• Constrictive pericarditis
• Hypoalbuminaemia (any cause)
• Peritoneal dialysis

Examiner Notes:

• Accept: Correct application of each Light's criterion
• Do not accept: Describing Light's criteria incorrectly, listing exudate causes instead of transudate

---

Question 2 (6 marks)

Stem: A 45-year-old woman has a complicated parapneumonic effusion with a chest drain in situ for 3 days. Despite appropriate antibiotics, she remains febrile with ongoing purulent drainage. CT shows a loculated effusion.

Question: a) Describe the intrapleural fibrinolytic regimen recommended by the MIST2 trial. (3 marks) b) What were the key outcomes demonstrated by this trial? (2 marks) c) List 2 indications for surgical referral in empyema. (1 mark)

Model Answer:

a) MIST2 regimen (3 marks):

• tPA (tissue plasminogen activator) 10mg + DNase (dornase alfa) 5mg (1 mark)
• Each diluted in 30ml normal saline, instilled intrapleurally (0.5 mark)
• Dwell time 1 hour (clamp drain) then release (0.5 mark)
• Given twice daily for 3 days (total 6 doses) (1 mark)
• Note: tPA alone or DNase alone is NOT effective - must use combination

b) Key MIST2 outcomes (1 mark each, max 2):

• Reduced need for surgical referral (4% vs 16% in placebo group)
• Reduced hospital length of stay (approximately 6 days shorter)
• Improved radiographic resolution
• No significant increase in bleeding complications

c) Surgical referral indications (0.5 mark each, max 1):

• Persistent sepsis despite adequate drainage and antibiotics
• Failure of intrapleural fibrinolytics
• Trapped lung (thick pleural peel preventing re-expansion)
• Loculated effusion not responding to medical management
• Bronchopleural fistula

Examiner Notes:

• Accept: Correct doses and regimen for MIST2
• Do not accept: Using tPA alone, incorrect dosing, describing medical management for surgical indications

---

Question 3 (6 marks)

Stem: A 55-year-old man develops sudden cough, chest tightness, and falling SpO2 during therapeutic thoracentesis for a massive pleural effusion present for 3 weeks. You have drained 2L.

Question: a) What complication has occurred? (1 mark) b) List 4 risk factors for this complication. (2 marks) c) Outline your immediate management (4 steps). (2 marks) d) Why are diuretics NOT indicated? (1 mark)

Model Answer:

a) Diagnosis (1 mark):

• Re-expansion pulmonary oedema (REPE)

b) Risk factors (0.5 mark each, max 2):

• Duration of lung collapse greater than 72 hours (3 weeks in this case)
• Volume drained greater than 1.5L (2L in this case)
• Rapid rate of drainage
• Large initial effusion (greater than 3L)
• Young patient age
• First thoracentesis for the effusion
• Low pleural elastance (trapped lung)

c) Immediate management (0.5 mark each, max 2):

• Stop drainage immediately (clamp/remove needle)
• High-flow oxygen 15L via non-rebreather
• Position upright if tolerated
• Consider NIV (BiPAP) if not responding to oxygen
• Monitor SpO2 continuously
• Prepare for intubation if severe
• Supportive care (usually resolves 24-48 hours)

d) Why diuretics NOT indicated (1 mark):

• REPE is non-cardiogenic pulmonary oedema caused by increased capillary permeability (NOT hydrostatic overload)
• Mechanism is hypoxia-reoxygenation injury and inflammatory mediator release
• Diuretics are ineffective and may cause harmful hypovolaemia

Examiner Notes:

• Accept: Clear recognition of REPE, appropriate risk factors, supportive management approach
• Do not accept: Suggesting diuretics, failing to recognise the complication

---

Question 4 (6 marks)

Stem: A 3-year-old Aboriginal child from a remote community presents with a 5-day history of cough, fever, and respiratory distress. Ultrasound confirms a large right-sided empyema with septations.

Question: a) What organisms are particularly important to consider in this population? (2 marks) b) What is your empiric antibiotic regimen and why? (2 marks) c) List 2 social/health system factors that may contribute to delayed presentation and more severe disease in Indigenous children. (2 marks)

Model Answer:

a) Important organisms (1 mark each, max 2):

• Streptococcus pneumoniae (most common, but serotype replacement post-vaccination)
• Staphylococcus aureus including CA-MRSA (community-associated MRSA more prevalent)
• Streptococcus pyogenes (Group A Strep) - causes severe pleuropulmonary infections
• Polymicrobial infections (if underlying bronchiectasis)

b) Antibiotic regimen (2 marks):

• Ceftriaxone 50mg/kg IV daily (covers S. pneumoniae, GAS, most respiratory pathogens) (1 mark)
• PLUS Vancomycin 15mg/kg IV 6-hourly (covers CA-MRSA, which is more prevalent in Indigenous communities) (1 mark)
• Rationale: Higher CA-MRSA prevalence in Aboriginal communities means empiric coverage is warranted until cultures return

c) Social/health system factors (1 mark each, max 2):

• Geographic remoteness - limited access to primary healthcare, long distances to hospitals
• Overcrowded housing - increased respiratory pathogen transmission
• Reduced access to primary care - delays in initial antibiotic treatment for pneumonia
• Nutritional deficiencies - impaired immune function
• Distrust of healthcare system - historical trauma leading to delayed presentation
• Language/cultural barriers - difficulty communicating symptoms
• Limited local resources - no ultrasound, limited procedural expertise

Examiner Notes:

• Accept: Recognition of CA-MRSA risk, appropriate antibiotic choice with rationale
• Do not accept: Failing to add vancomycin, not recognising Indigenous-specific epidemiology

---

Australian Guidelines

ARC/ANZCOR

• ANZCOR Guideline 11.5: Reversible causes of cardiac arrest (4Hs and 4Ts) - tension hydrothorax as a T (Tension)
• Key point: Massive pleural effusion can cause obstructive shock similar to tension pneumothorax

Therapeutic Guidelines Australia

• Antibiotic Expert Group: Empiric antibiotics for empyema
  • "Adults: Ceftriaxone 2g IV daily + Metronidazole 500mg IV 8-hourly"
  • Add vancomycin if MRSA suspected
  • "Duration: IV for minimum 10-14 days, then oral to complete 4-6 weeks total"
• Consider local resistance patterns in Indigenous communities

British Thoracic Society Guidelines 2023 [18]

• Ultrasound guidance for thoracentesis is standard of care
• Small-bore drains (10-14F) are as effective as large-bore for empyema
• Regular flushing (20ml saline every 6 hours) prevents drain blockage
• Early use of intrapleural fibrinolytics (tPA + DNase) for loculated effusions
• Surgical referral if fails to respond within 5-7 days

State-Specific

• NSW Clinical Guidelines: Retrieval criteria for pleural infection
• QLD Health: Paediatric empyema management pathway
• RFDS protocols: Chest drain mandatory before air retrieval of pleural effusion

---

References

Guidelines

1. Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346(25):1971-1977. PMID: 12075059
2. Havelock T, Teoh R, Laws D, Gleeson F. Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii61-76. PMID: 20696688

Key Evidence

3. Davies HE, Davies RJ, Davies CW. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii41-53. PMID: 20696693
4. Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg. 2007;84(5):1656-1661. PMID: 17954079
5. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011;365(6):518-526. PMID: 21830966
6. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Chest. 1993;104(5):1486-1489. PMID: 8222812
7. Mattison LE, Coppage L, Alderman DF, Herlong JO, Sahn SA. Pleural effusions in the medical ICU. Chest. 1997;111(4):1018-1023. PMID: 9106583
8. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006;3(1):75-80. PMID: 16493154
9. Maskell NA, Batt S, Hedley EL, Davies CW, Gillespie SH, Davies RJ. The bacteriology of pleural infection by genetic and standard methods and its mortality significance. Am J Respir Crit Care Med. 2006;174(7):817-823. PMID: 16840746
10. Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii32-40. PMID: 20696691
11. Porcel JM, Vives M, Cao G, Esquerda A, Rubio M, Rivas MC. Measurement of pro-brain natriuretic peptide in pleural fluid for the diagnosis of pleural effusions due to heart failure. Am J Med. 2004;116(6):417-420. PMID: 15006592
12. O'Grady KA, Torzillo PJ, Chang AB. Hospitalisation of Indigenous children in the Northern Territory for lower respiratory illness in the first year of life. Med J Aust. 2010;192(10):586-590. PMID: 20477734
13. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603-661. PMID: 26016486
14. Zhao Y, Thomas SL, Guthridge SL, Wakerman J. Better health outcomes at lower costs: the benefits of primary care utilisation for chronic disease management in remote Indigenous communities in Australia's Northern Territory. BMC Health Serv Res. 2014;14:463. PMID: 25288391
15. Gardiner FW, Bishop L, Gale L, Ranson D, Burdon R. The Royal Flying Doctor Service 2018 annual report on aeromedical retrievals. Emerg Med Australas. 2020;32(1):82-89. PMID: 31729163
16. Heffner JE, Brown LK, Barbieri C, DeLeo JM. Pleural fluid chemical analysis in parapneumonic effusions. A meta-analysis. Am J Respir Crit Care Med. 1995;151(6):1700-1708. PMID: 7767510
17. Diacon AH, Brutsche MH, Solèr M. Accuracy of pleural puncture sites: a prospective comparison of clinical examination with ultrasound. Chest. 2003;123(2):436-441. PMID: 12576363
18. Psallidas I, Helm EJ, Maskell NA, Yarmus L, Thomas R, Rahman NM. BTS Clinical Statement on pleural procedures. Thorax. 2023;78(Suppl 3):s1-s42. PMID: 37339846
19. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77(4):507-513. PMID: 4642731
20. Roth BJ, O'Meara TF, Cragun WH. The serum-effusion albumin gradient in the evaluation of pleural effusions. Chest. 1990;98(3):546-549. PMID: 2394139
21. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest. 2000;118(4):1158-1171. PMID: 11035692
22. Gordon CE, Feller-Kopman D, Balk EM, Smetana GW. Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med. 2010;170(4):332-339. PMID: 20177035
23. Petersen S, Freitag M, Albert W, Tempel S, Lehmann T, Eichfeld U. Ultrasound-guided thoracentesis is associated with low rate of complications. Ultraschall Med. 2014;35(2):149-152. PMID: 24327513
24. Mahfood S, Hix WR, Aaron BL, Blaes P, Watson DC. Reexpansion pulmonary edema. Ann Thorac Surg. 1988;45(3):340-345. PMID: 3348708
25. Rahman NM, Maskell NA, Davies CW, et al. The relationship between chest tube size and clinical outcome in pleural infection. Chest. 2010;137(3):536-543. PMID: 19820073
26. Spencer DA, Iqbal SM, Hasan A, Hamilton L. Empyema thoracis is still increasing in UK children. BMJ. 2006;332(7553):1333. PMID: 16740556
27. Thomson AH, Hull J, Kumar MR, Wallis C, Balfour Lynn IM. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax. 2002;57(4):343-347. PMID: 11923554
28. Ministry of Health New Zealand. Tatau Kahukura: Maori Health Chart Book 2015. Wellington: Ministry of Health; 2015.
29. Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis. 2007;45(11):1480-1486. PMID: 17990232
30. Villena Garrido V, Cases Viedma E, Fernández Villar A, et al. Recommendations of diagnosis and treatment of pleural effusion. Update. Arch Bronconeumol. 2014;50(6):235-249. PMID: 24698396
31. Hooper C, Lee YC, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65 Suppl 2:ii4-17. PMID: 20696690
32. Porcel JM. Chest tube drainage of the pleural space: a concise review for pulmonologists. Tuberc Respir Dis (Seoul). 2018;81(2):106-115. PMID: 29617100
33. Baumann MH, Strange C, Heffner JE, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest. 2001;119(2):590-602. PMID: 11171742
34. Brims FJ, Lansley SM, Waterer GW, Lee YC. Empyema thoracis: new insights into an old disease. Eur Respir Rev. 2010;19(117):220-228. PMID: 20956197
35. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med. 2006;119(10):877-883. PMID: 17000221
36. Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of empyema therapy. Chest. 1997;111(6):1548-1551. PMID: 9187172
37. Piccolo F, Popowicz N, Wong D, Lee YC. Pleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. J Thorac Dis. 2015;7(6):999-1008. PMID: 26150912
38. Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis. 2010;50(6):805-813. PMID: 20166818